Quest Diagnostics (DGX 6.99%) reported its second-quarter 2025 results on July 22, achieving consolidated revenue of $2.76 billion (up 15.2% year over year), organic revenue growth of 5.2%, while adjusted EPS rose 11.5% year over year to $2.62. Management raised full-year revenue guidance to $10.8 billion to $10.92 billion and adjusted EPS to $9.63 to $9.83, citing sustained demand for advanced diagnostics, the integration of last year's LifeLabs acquisition, and scale-driven productivity gains. Investors s ...